Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

XSB-1E as possible Alzheimer's treatment

June 14, 1996

MF-8622 undergoes preclinical evaluation

June 14, 1996

NN-42-1007: First potent and selective hepatic glycogen phosphorylase inhibitor

June 7, 1996

Ongoing evaluation of Pharmacia & Upjohn's new water-soluble camptothecin derivative

June 7, 1996

A7-183: Effective topical therapy of recurrent herpes labialis and genitalis

June 7, 1996

Protein farnesyltransferase inhibitor from Banyu and Merck & Co.

May 31, 1996

Small-molecule alpha4 integrin antagonists generation disclosed by Biogen

May 31, 1996

Potential hypoxic marker synthesized by Evanston Hospital

May 31, 1996

PKC pathway activation may have therapeutic significance in bone disease management

May 31, 1996

OC104-26 identified as multidrug resistance (MDR)-reversing agent

May 31, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.